Skip to main content

Table 1 CD73 and CD39: Predictive and Prognostic Biomarkers

From: Targeting adenosine for cancer immunotherapy

  Tumor Type Findings # of Patients Study Author
Negatively prognostic NSCLC (stage I-III) High CD73 expression was an independent risk factor for decreased overall survival and dereased recurrence-free survival 642 Inoue, et al. [54]
Prostate Cancer CD73 expression in normal tissue was a negative prognostic factor for prostate-infiltrating CD8(+) cells. However, high expression of CD73 in tumor stroma was associated with longer recurrence-free survival 285 Leclerc, et al. [55]
Breast Cancer (Triple Negative) CD73 expression is associated with anthracycline resistance and poor prognosis 6000 Loi, et al. [56]
High-Grade Serous Ovarian Cancer High levels of CD73 are associated with shorter disease-free survival and overall survival 1581 Gaudreau, et al. [57]
Colorectal Cancer (stage I-IV) High expression of CD73 predicts poor survival 223 Wu, et al. [58]
Gastric Cancer (stage I-IV) High expression CD73 is associated with lowered overall survival 68 Lu, et al. [65]
Melanoma (Stage IV) High soluble CD73 activity was associated with poor overall survival and poor progression-free survival 37 Morello, et al. [59]
Head and Neck Cancer (stage I-IV) High levels of CD73 are associated with reduced overall survival 162 Ren, et al. [60]
Renal Cell Cancer (Stage I-IV) High expression of CD73 is associated with disease progression and shortened overall survival 189 Yu, et al. [2]
Positively prognostic Nonmuscle-Invasive Urothelial Bladder Cancer High CD73 iactivity was associated with favorable clinicopathological features. Furthermore, predicts better outcome in the subgroup of pTa and pT1 tumors. 174 Wettstein, et al. [61]
Breast Cancer (stage I-III) CD73 expression strongly correlated with longer disease-free survival and overall survival 136 Supernat, et al. [62]
Endometrial Carcinoma (endometrial endometrioid carcinomas, Grade 1–3) and nonendometrioid uterine papillary serous carcinomas CD73 is markedly downregulated in poorly differentiated and advanced-stage disease compared with levels in normal endometrium and low-grade tumors 49 Bowser, et al. [64]
Colorectal cancer (Stage IV) High CD73 expression was associated with longer progression free survival from cetuximab treatment in patients with KRAS-WT and KRAS-mutant tumors 238 Cushman, et al. [63]
Negatively prognostic Gastric Cancer (stage I-IV) High CD39 expression is a predictor of poor outcome following radical resection 101 Cai, et al. [69]
Hepatocellular carcinoma High CD39 expression is an independent indicator of decreased overall suvival after radical resection 324 Cai, et al. [70]
Chronic lymphocytic leukemia CD39 expression on CD4+ lymphocytes are increased in the peripheral blood of patients with CLL and correlates with advanced stage of disease 62 Perry, et al. [71]